Management of conjunctival malignant melanoma

A review and update

James R. Wong, Afshan A. Nanji, Anat Galor, Carol Karp

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.

Original languageEnglish
Pages (from-to)185-204
Number of pages20
JournalExpert Review of Ophthalmology
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Melanoma
Epidemiology
Biological Therapy
Drainage
Tumors
Tissue
Neoplasms
Therapeutics

Keywords

  • BRAF inhibitors
  • Conjunctival malignant melanoma
  • Dabrafenib
  • IFNa-2b
  • Ipilimumab
  • Melanoma mitomycin C
  • Ocular neoplasm
  • Vemurafenib

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Management of conjunctival malignant melanoma : A review and update. / Wong, James R.; Nanji, Afshan A.; Galor, Anat; Karp, Carol.

In: Expert Review of Ophthalmology, Vol. 9, No. 3, 01.01.2014, p. 185-204.

Research output: Contribution to journalArticle

@article{0f3c50caae754c3a9416c4b42a4c3cc2,
title = "Management of conjunctival malignant melanoma: A review and update",
abstract = "Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.",
keywords = "BRAF inhibitors, Conjunctival malignant melanoma, Dabrafenib, IFNa-2b, Ipilimumab, Melanoma mitomycin C, Ocular neoplasm, Vemurafenib",
author = "Wong, {James R.} and Nanji, {Afshan A.} and Anat Galor and Carol Karp",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/17469899.2014.921119",
language = "English",
volume = "9",
pages = "185--204",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Management of conjunctival malignant melanoma

T2 - A review and update

AU - Wong, James R.

AU - Nanji, Afshan A.

AU - Galor, Anat

AU - Karp, Carol

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.

AB - Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.

KW - BRAF inhibitors

KW - Conjunctival malignant melanoma

KW - Dabrafenib

KW - IFNa-2b

KW - Ipilimumab

KW - Melanoma mitomycin C

KW - Ocular neoplasm

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84901254588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901254588&partnerID=8YFLogxK

U2 - 10.1586/17469899.2014.921119

DO - 10.1586/17469899.2014.921119

M3 - Article

VL - 9

SP - 185

EP - 204

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 3

ER -